Development of therapeutic IgA molecules and expression platform for SARS-CoV (Q3069477): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): The aim of the project is to develop a development platform for antiviral antibody candidates for medicinal products. The project will develop technologies for the development and production of antibodies based on secretory immunoglobulin A. In order to validate the novel approach, animal testing shall be carried out on antibodies against SARS-CoV-2 developed by the applicant, leading to secretory immunoglobulin A antibody isotype., translated_s...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Development of therapeutic IgA molecules and expression platform for SARS-CoV | |||
Revision as of 11:59, 16 August 2021
Project Q3069477 in Estonia
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of therapeutic IgA molecules and expression platform for SARS-CoV |
Project Q3069477 in Estonia |
Statements
2,968,871.71 Euro
0 references
3,718,589.64 Euro
0 references
79.84 percent
0 references
1 February 2021
0 references
31 December 2023
0 references
Icosagen Cell Factory OÜ
0 references
61713
0 references
Projekti eesmärk on välja töötada viirusvastastel antikehadel pōhinev ravimikandidaatide arendusplatvorm. Projekti käigus arendatakse välja tehnoloogiad sekretoorse immunoglobuliin A põhiste antikehade arendamiseks ja tootmiseks. Uudse lähenemise valideerimiseks viiakse läbi loomkatsetused taotleja arendatud SARS-CoV-2 vastaste antikehadega, mis pōhinevad sekretoorse immunoglobuliin A antikeha isotüübil. (Estonian)
0 references
The aim of the project is to develop a development platform for antiviral antibody candidates for medicinal products. The project will develop technologies for the development and production of antibodies based on secretory immunoglobulin A. In order to validate the novel approach, animal testing shall be carried out on antibodies against SARS-CoV-2 developed by the applicant, leading to secretory immunoglobulin A antibody isotype. (English)
16 August 2021
0 references
Identifiers
2014-2020.4.02.21-0314
0 references